PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annua





PROLOR Biotech, Inc. , today announced that the company will present preclinical data on its long-acting clotting Factor VIIa (Factor Vlla-CTP) at the 54th Annual Meeting of the American Society of Hematology (ASH). The data will be discussed by Dr. Gili Hart, Director of Pre-Clinical Affairs at PROLOR and head of the company’s long-acting clotting factors program, in an oral poster presentation on December 8, 2012. PROLOR’s Factor VIIa-CTP is in advanced preclinical development for the treatment of hemophilia. Top-line results of the Factor Vlla-CTP studies have been previously reported by PROLOR. The results show that when compared to commercially available Factor VIIa, Factor VIIa-CTP in hemophilic mice demonstrated a markedly enhanced pharmacokinetic profile and increased exposure, as evidenced by a prolonged hemostatic effect and improved recovery, which is a measure of clotting activity. Compared to commercially available Factor VIIa, Factor VIIa-CTP in hemophilic mice demonstrated superior thrombin generation parameters, and it resulted in greater survival of the subjects. In these studies, the specific activity of Factor VIIa-CTP was comparable to commercial Factor VIIa. The study data also show that administration of Factor Vlla-CTP by subcutaneous injection resulted in improved bioavailability and prolonged exposure compared to intravenous administration of Factor Vlla-CTP. PROLOR CEO Dr. Abraham Havron commented, “The ASH Annual Meeting is the largest and most prominent gathering of hematology experts in the world. In preclinical studies our long-acting clotting factors have demonstrated the potential to significantly improve both the prophylactic and on-demand treatment of patients with hemophilia, and we welcome the opportunity to share these promising data with leading hematology researchers.” Dr. Hart will present PROLOR’s poster, “Factor VIIa-CTP,a Novel Long-Acting Coagulation Factor with Enhanced Long Term Haemostatic Effect and Improved Pharmacokinetics and Pharmacodynamic Properties Following IV Administration in Hemophilic Animal Models,” on December 8, 2012 at 5.30 pm EST. The 2012 ASH Annual Meeting is being held December 8-11, 2012 in Atlanta, Georgia. ABOUT PROLOR PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology and its long-acting reversible-pegylation technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins. PROLOR is developing a long-acting version of human growth hormone, which successfully completed a Phase II clinical trial. It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development.